SciELO - Scientific Electronic Library Online

 
vol.79 número3Cirugía neonatal maxilofacial: 10 años de experiencia (1994 a 2005)Aspectos clínico-terapéuticos de la púrpura de Schönlein-Henoch índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Pediatría

versión On-line ISSN 1561-3119

Resumen

VALDIVIA ALVAREZ, Ileana et al. Efficacy of Vigabatrin in refractory epilepsy in children. Rev Cubana Pediatr [online]. 2007, vol.79, n.3, pp. 0-0. ISSN 1561-3119.

The therapeutical response to Vigabatrin in add-on therapy was evaluated in 28 patients diagnosed with refractory epilepsy and hospitalized at Neuropediatric Service of Juan Manuel Márquezpediatric hospital from January 2002 to July, 2005. Variables such as sex, age at admission, onset of epilepsy, type of seizure, etiological diagnosis, previous drug failures, type of multitherapy and response one, three, six months and 1 year after treatment and adverse reactions to medication. It was concluded that epilepsy has an early onset, is the result of hypoxic damage and structural lesions of the brain in over 70% of cases, failed therapy with 2 to 4 drugs and that the most accepted multi-therapy was Valproate. Positive response to treatment occured in 67,9% of cases, seizures were half-reduced in 21,4% of the patients after one year of treatment. Epileptic spams associated to partial seizures showed later response than spams as the only form of seizure. Vigabatrin was well-tolerated and its adverse effects were transient and slight.

Palabras clave : refractory epilepsy; children; Vigabatrin; adverse effects.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License